Gilead Sciences, Inc.

GILD Healthcare Drug Manufacturers General

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.

170.84 5.23 +3.16%
Market cap
$205.4B
P/E
0.0×
Fwd P/E
−45.5×
Dividend yield
1.90%
F-score
8/9
Altman Z
4.03
Beneish M
−2.45
Dividend safety
77/100

Gilead Sciences, Inc. (GILD) EV/FCF

Alert me on EV/FCF

As of 30 October 2026, Gilead Sciences, Inc. (GILD) trades at a EV/FCF of 18.2×. Over the past ten years it has ranged from 5.9× (December 2016) to 22.3× (February 2026); the current reading is higher than 97% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 18.0× 40.45%
FY2024 12.8× (22.70%)
FY2023 16.6× 8.63%
FY2022 15.2× 46.60%
FY2021 10.4× (20.59%)
FY2020 13.1× 30.03%
FY2019 10.1× (5.26%)
FY2018 10.6× 13.99%
FY2017 9.3× 32.44%
FY2016 7.0× (7.46%)

Quarterly newest first

Period EV/FCF Change
Jun 2026 13.9× (24.13%)
Mar 2026 18.3× 2.02%
Dec 2025 18.0× 5.88%
Sep 2025 17.0× 0.83%
42 more quarters

Against its own ten years

Low 5.9× High 22.3×
Ten-year median 11.7×
Current reading's percentile 96

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on GILD